Blog

Biosimilars are, as the name would suggest, highly similar and are a more affordable alternative to biologics that is poised to influence the current dynamics of the immunology market. ...
The U.S. immunology drug market is expected to grow to $68 billion by 2023 due to the entry of new biosimilars and JAK inhibitors....
Our iData Research Spine Team will be attending the 32nd North American Spine Society (NASS) Annual Meeting at the Orange County Convention Center in Orlando, Florida on October 25-27. Please visit us on the show floor at booth #250 and...
ZEISS CLARUS 500 aids ocular disease detection with exceptional True Color imaging clarity from the macula to periphery...
Mizuho OSI is the market leader in developing specialty surgery tables for orthopedic, spine, and trauma surgery....
Pantheris Image-Guided Atherectomy Device Designed to Empower Physicians to Precisely Treat Peripheral Artery Disease...
As minimally invasive devices continue to gain popularity in the surgical community, the number of MIS interbody fusion procedures performed in Europe will reach nearly 38,000 by 2023...
This market’s value is expected to continue growing, demonstrating similar growth patterns in each of the resorbable and non-resorbable solutions. Nonetheless, market growth is threatened by increased competition. ...
These newly introduced products join Trabexus EB, which first received 510(k) clearance in 2015. TRABEXUS EB is a self-setting, gradually resorbable, calcium phosphate matrix enhanced with partially demineralized allograft particles....
Sandoz believes the comprehensive data package submitted to the FDA for review confirms that our biosimilar rituximab matches the reference medicine in terms of safety, efficacy and quality...
close-link
close-link
close-link

Subscribe to MedTech Market News - Get exclusive analyst articles, monthly newsletters and iData offers

close-link
close-link